Technical analysis of Adial Pharmaceuticals, Inc. (ADIL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
Price Performance
| 1 month | -3.85% |
| 3 months | +101.54% |
| Year-to-date | -4.73% |
| 1 year | -40.11% |
| 3 years | -92.51% |
| 5 years | -99.80% |
52-Week Range
| 52-week High | $10.75 |
| 52-week Low | $1.31 |
| Avg Volume (90d) | 336K |
Technical Indicators
| SMA 50 | $4.40 |
| SMA 200 | $3.64 |
| 30-day Volatility (annualised) | 143.7% |
| Price vs SMA 50 | +19.0% |
| Price vs SMA 200 | +44.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.75 | |
| 2025-11 | $7.75 | -11.4% |
| 2025-12 | $5.50 | -29.0% |
| 2026-01 | $5.25 | -4.5% |
| 2026-02 | $2.53 | -51.8% |
| 2026-03 | $1.79 | -29.2% |
| 2026-04 | $1.54 | -14.0% |
| 2026-05 | $2.40 | +55.8% |
| 2026-06 | $2.56 | +6.7% |
| 2026-07 | $3.34 | +30.5% |
| 2026-08 | $5.75 | +72.2% |
| 2026-09 | $5.24 | -8.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $5.24 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 155.24 |
| EV / EBITDA | 0.38 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.63 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -20.02 |